-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Fl196iJuj5ChM9aw/JgRoKe4iMtfA6XBYCfuqIh4XKuYYAFjMYpOxXUrsq+vr2L2
 FSzVIk6YMki8YT4i9x1fVQ==

<SEC-DOCUMENT>0001144204-08-057041.txt : 20081010
<SEC-HEADER>0001144204-08-057041.hdr.sgml : 20081010
<ACCEPTANCE-DATETIME>20081010141741
ACCESSION NUMBER:		0001144204-08-057041
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20081010
FILED AS OF DATE:		20081010
DATE AS OF CHANGE:		20081010

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		081117939

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v128567_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;

      <div>
        <hr style="COLOR: black" align="left" noshade size="2" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      month of October 2008</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Biopharmaceuticals Ltd.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font>&#160;</div>
    <div>
      <hr style="COLOR: black" align="center" noshade size="1" width="40%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
      Cottage, New York 10989</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <hr style="COLOR: black" align="center" noshade size="1" width="40%">&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F&#160;<u>&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x </font></u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F&#160;<u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: Wingdings">&#160;</font></u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule
      101(b)(1):&#160;<u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: Wingdings">&#160;</font></u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule
      101(b)(7):&#160;<u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: Wingdings">&#160;</font></u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes&#160;<u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: Wingdings">&#160;</font></u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No&#160;<u>&#160;&#160;&#160;&#160;</u><font style="DISPLAY: inline; FONT-FAMILY: Wingdings"><u>x
      </u>&#160;</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <hr style="COLOR: black" align="left" noshade size="2" width="100%">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Incorporation
      by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated October 7,
      2008
      is hereby incorporated by reference into the registration statements on Form
      F-3
      (File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by
      XTL
      Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March
      23,
      2007 , October 30, 2007 and August 15, 2008, respectively, and the registration
      statements on Form S-8 (File No. 333-148058 and File No. 333-148574) filed
      by
      XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on
      December 14, 2007 and January 18, 2008, respectively.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="logo.jpg" alt=""></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Extraordinary
      General Meetings Statement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>&#8212;
      XTL Notifies NASDAQ of Compliance with Marketplace Rule
      4350(d)(2)</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
      Cottage, New York, October 10, 2008</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      - XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) announces the results of
      its
      Extraordinary General Meetings (&#8220;EGMs&#8221;) held earlier today.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      outcome of the EGMs was as follows: all of the resolutions passed and Jennifer
      L. Good and Kenneth J. Zuerblis were appointed as External Directors of the
      Company until October 10, 2011. Following the EGMs, XTL&#8217;s Audit Committee
      consists of Mr. Zuerblis, Ms. Good and Dr. William Kennedy. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">With
      the
      election of the External Directors by the shareholders and their automatic
      inclusion in the Audit Committee, XTL has notified NASDAQ that it currently
      has
      a valid Audit Committee under the Israeli Companies Act and NASDAQ Marketplace
      Rule 4350(d)(2).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ABOUT
      XTL
      BIOPHARMACEUTICALS LTD.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
      for the treatment of diabetic neuropathic pain and HCV. XTL is developing
      Bicifadine, a triple reuptake inhibitor of serotonin, norepinephrine and
      dopamine, which is currently in a Phase 2b study for the treatment of diabetic
      neuropathic pain. XTL has out-licensed its novel pre-clinical HCV small molecule
      inhibitor program. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock
      Exchanges (NASDAQ: XTLB; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(845)-267-0707 ext. 225</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="50%">&#160;</td>
            <td align="left" colspan="2" valign="top" width="50%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL&#160;BIOPHARMACEUTICALS&#160;LTD.</strong></font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="50%">&#160;</td>
            <td align="left" valign="top" width="3%">&#160;</td>
            <td align="left" valign="top" width="47%">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="top" width="50%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="TabDataBeginIP"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                October 10, 2008</font></a></div>
            </td>
            <td align="left" valign="top" width="3%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:
                </font></div>
            </td>
            <td align="left" valign="top" width="47%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/
                Ron Bentsur</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="50%">&#160;</td>
            <td align="left" valign="top" width="3%">&#160;</td>
            <td align="left" valign="top" width="47%">
              <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
                Bentsur</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="50%">&#160;</td>
            <td align="left" valign="top" width="3%">&#160;</td>
            <td align="left" valign="top" width="47%">
              <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief&#160;Executive&#160;Officer</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`0`"D`P$1``(1`0,1`?_$`-`````%!0$!````````
M```````("0H+`0(#!@<$!0$``0,%`0``````````````"``%!P$"`P8)!!``
M``4#`@,$!0,."0T``````0(#!`41!@<`""$2"3%!41,B%!46"K$R&&%Q@9%B
M(S.UUA=WEW@YP=%2<K:W.%@9\*'A\4*"DJ)#)"8G&A$``0($!`(&!0<'"@<`
M`````0(#`!$$!2$2!@<Q05%A<2(3"(&1L3(4H='A=!46-L'Q0G(C<U3P8H*2
MLM(S)!<84D-3-"4F"?_:``P#`0`"$0,1`#\`?XE/7_:[?'E#Y=8LI'O."7HB
MT+)]U"H^7.3D5;D1+W#./4HZ&@8M_,RTBN(^KL8N+:K/G[Q82%,/EM6K<YS4
M`1H'9JK27GWTTE+)2W"`,1/,3(`#G"==2Q3J>?[K:02>P"&6V1_BSIV+SC(-
M<8[5[=NC;W$S[F/:S5P7I+Q>4+N@&;HS8]RQS=JS<6S;ZS]!,%FK-<CK[V8`
M56((CRDI;/+S5UMD0IVM`O!3F")=V7$SYS`Z\>40G6;PL-W`T[")T220>,YC
MACPXP[OVY9YL+<Y@K&6X#&3YP]L3*]IQ]X6^=VF",@W:R`&!U&R"("8$)"(?
MIJM7!`$0*LB8`$0XZ'F\VRJM%YJ+/5+2':=1!]!E.?0>,2[:+@W>;:S7-8(>
M3,=/9VQVSG`M`'F$>-`X5X>`4[_M:;TK4@959)]OTQ[U35CD.$5Y_NN_O'Y!
MX5#54A!F7<H43R/+UQ=/-Q"@>H?1`YON@^WJ^5/TCU_3"E^OZOH@<WW0?;TI
M4_2/7],*7Z_J^B!S?=!]O2E3](]?TPI?K^KZ(`'"M.:HT`1#NH/"M?\`*FK<
M["591QZIF%EGB29=<92TKW=G=_KUEXB?*+!X85)/O1?JD7QXS"5,@%,)C`)A
MIR@/CW4X]^L/BEIPK?4`#PPPBW.ZT)D*6OJ'*/0E00-0PF#F&E:<`X<.%.S5
MZ)R)*@J9GAT=$41(@D$F9Y\CT1<<H&`*]P@/VOX-4=&9,NN+BD*E/D9QYS&Y
M3<I1H%.80[:_7\!_@#5KCJU(_9`E73"ROK6%S`;$4*<JH%Y3U+XTX^/U.VO#
MAJX/M-KRJ6"L\IB+E-`=UT%2O5'H3IRT"O`1^=P'Y`X:S*XQ:$Y1(`#Y8OU;
M%8&E"@:4*$C>L;/[YL9[3YK.>Q#(QK5OO"[AW>&0;-]RK:O0U]8R*U'WB-%M
M)Z-D5T)RT2)ED$P;@'K#8BY!`3<FMSV^IM.5FH6K?J=)%N?.5"DG*0KEF)G@
M>P1JNLG+S2VI=;:%D/($SPX=([(9V8'^(9WN2>6+1@MV^58[)VV2\7+NQLU6
MM&8\LFW)%SCB^6#BV)V<BIB%B6,DREK:92AGZ()J"50R`D,4Y3!HGK_LM8*2
MUKK["TL7=@!Q@A4TKE(IGT@RD9$83B#[)KR]5%R%'=G/$MSBLCA5.:1+'+P`
ME.8G.-HN[X9C?2XRDUBL%36',C;?+F=HRV/<[.\@-(=HGCV<,@]MR6G;0.T<
M7`O*MH9VF91)@5TBY.4!24Y1&GGM.^^FZ.T@79MQ%^82I"V4@Y0L3"1P)E,2
M5WO5./74[3W!^YKJJ%2569Y0*22"HI5BHX$<`9B8X\1'U-T?5SW!;`KFL783
MT^,QQD=A79_8C+#USY`>V5:%U*Y>S"W?/9;)]WM3S[.6-&PS2[I!RS9IH'`@
M`BH)A/4!#QZ;VPM^K6W=7ZQ;4S5W1>9I"#)*$GW9S!,S@<3S/&,FHM95>EGF
MM/V93?P5(D`*QS*(XYI&1'4`F%C-@.[#JC9'Z;N\W?WN/S@0\;#X0R6^VM6^
M.,K#@Q-,V3"R$@^RW(@Q@6QY*+]L,RL8QNJ(M7!$EU3$,44QU%FMM-Z-H]<6
M_1VGDA=0XXD.K4K,D8B8!!$L.,YQO5@O&H7M*5EZNBE"K:22VD2D1E)$P03Q
MEP(PG#=4GQ%?5E*4O-N7M\]2D&H8AQ=WD*(\0MT0[1T0"-BM#)P4`H)'>(7S
ME,RQB)_]3=7JF4K"<3@1U]8C,7XB7JV'#G)N/@C$K3F##^,#!7APY@MVE=)>
MRFWBA-AEU77GF/DC&=TM5I[JG4^)QE(</5%!^(GZM11Y3;E+>((A4`-B#%X<
M/'C;X:H-D-!`Y7$%*STK^F*)W5U6<<Y*>I(_NQ0/B)^K77E^DI;IC>!,08O$
M?'L"WS#K(UL5H12@AP)*U<,J_IBJMT]62SI40CK2/[L'EZ:/6YZE&XO?QM8P
MCEO.L3<6-\E9096W>,(VQCC^'6E(96(F7:C0DG&P2#YGSKM"#SI'*?AVZU/<
M#:+2&G-*5]VMZ%BLIF@I/>F)DRQY_+#]I77=_O.H:6@KES:>7E,L,/5+Y(?\
M)B(C3N*`@`!\OU]!TE16$.'BH>B"/2D)1(<C&;62%#>W(F]C<M!=5>&VUQ>0
M46V''^5\>VLO:XVS;RJ_L6?MN,D)1L6948&E"G6=.#F`_F"8M:`--&99=G-%
MUWEX?W"J&W#J)%!4O`YADSM9LO=E.1ECCV2CGKJ'?/<"B\V%/MK150&F';A3
MTZD9059'`G/(\)B9D98=<.!T%/1$*#VC2H"/_,/AH+RA+)P4A+9$Y'C/U\(Z
M%KDAWPN\3*<Y8>L"49%#C0`X!S"`!P$1J/U0&FJ8NJDV4E',SQE%I25*R<N)
MPZ.OA!5]ZEZ9#QSM@S+?&*U'B61;<LYP_M)2-B2SKP)8CUBDF*$.9L]]HJ>0
MJI1/RC\`'AK=-N;=:KQK6W6J]+#>GGWLKRR0E21(XA1[HQEB08C7>"XZ@L^V
MEWO&F$J7?J5C/3H`*LZI@=Y*9$X$F0(@H72DSWN5SQC[*TON1=S;J9@+TAXZ
MV!F;)3LI4D,Z@".G8I-21<7Z\F9^!O3Y3\@^C7AJ2O,'I#0.CKY;Z?1+C3]*
M_3E3A0ZAZ2\TI`M\,.1G$2^5?5VY>J[!<']SDOMU=.^E+7BMEJ:2"3/,!/'H
MY0K(FI4H\O</$1[:]]0[=0(I2BG,D&?04D047<!/AY?#Z09B<5,J8*4IQ^Y-
M7[''LU0YBW/!*Y\P91ERDHFB2C/I$HOJ;MJ4/K@/\>KFPL#]I(GJP^>%AS!G
M&358MCPO62#YLY:.FR#ML[;K-'39TF19NY;.$S(KH.$5`,15!5(PE.00H8HB
M`ZQ@K0M+R`0[,<_=D>(BY8;=;4RYBVH$'TQ&1=<[IO.-@&[:1>V5$*H[=<]K
M2M\XB6*F8T?;,B=8%KQQB=7TDTC6R^<^<Q3$0$T6X2`*^6>AX[1:\5J/3#5,
M\4N7BB5X2D'BIH)!2OKG-0]$"GN%II[3]Q4XP)4%1B%#$YIXB7$2@YNV'KQW
M1@SI'Y(VQN9=^ONDLE1'$>W>XS)JN%D,2WFS?G5NER^Y%BED,1,R.6+0#G`Q
MSN&'+4"'UIFH]H$5^XK=TIDI%BJ`7G1,`AQ'>R9>,EJE/T]4/-MW$<H](*MZ
M7%?:;,D([IEE4<3FX`@>Z#"5'3`V#7CU%MVUHX;;^TD,=12Y+ZSU?*)E5SP.
M.H]X1622]>$!$+IO)\<&#*HB8ZZRBQ@HF80DO<?6+&@M(&XNI0NM=3D9:G[N
M'$`8X<8U;16G%:QO.>H4HLH5F<4<#QY3X]D2D##"^,8W%++!S:QK;-B%C9K;
M'J..G48U=6L>RVD8G#)6ZYBUR*-G<<I&I@DHFH!@4J)C5$1J`2ZZJ-0+@A1^
M/S9POF"3/CQ@LFZ6G8IC1(0#3E.4CJE*4%O_`,-;I]$`H#LGVQ@`<"@7#5B"
M!0"@`'&&#AP[-/2=9:M2"37O`&0E,\>V&-[2^GB0I5&T0.>(EZ)PQ$^(]P]B
M7!O4#B;&PSC>R,5VF;;_`(ZFUK7L"V8FU8%28D)R\TGLF,;#-6;4SMPBS3*9
M02B80(&BZV"KZNY:=<K[I4+>2'U)&8$GNR/R`B(!W6H[?;K^ABB:2V"S/#I,
MI>S&%C?AH-I.U_/NR?*UTYNV]8=RS<T;N+N*&87!D''UL75,-(A"RK+=(1;:
M2F(]V[18H.':IR)`8$RG5,(!41U&.^]_OEIU<BFMM0XTT6@9),A(GCVQNNUM
MEM-PT^MZM80XOQ)3(ZOI$'YZR>Q39GB[ID;NK_QQM7P+8=[VSCV*?6[=UIXO
ML^#N.%>J7M:[,[F+EF$4D[8KF;N3DYR&`0*<=:3MUJ>_U>M[;2U=8\II3X"@
M3,2D?FC9]9:>L])I9]RGIVT.MIG@.&/;#+[HQ\.JCL=[.&:XX!Y2@4HB%NW"
M41*`<:"(#Q-4PZ++==KPM`7I,Y@M@@]4Q$#:!4%:PH".'BF42JA?PGV-<[VO
M\-'88,+]`_K1GUFBR&F6;)-A$=;R)E91XWCHN)S5C"2DI!ZJFU:LF+&RXMT\
M=N'"ZB22"#9!,3G.8:`0!UTATH%O^4&I0RAQ:_@*EF24DDK<)"`D#B)D3(P$
M<DM;/4EM\[K-?5.(:IVKG3/+4M02$H0$E9)/"0$P.?*#FYLZ[..K5NJ3MK"&
M+'^4XV,>KM%KQF9\;8@Y+RSF3*Z@F+*.EY9PP<'((HN%@1!8E#%*!:",*Z5\
MHVIKU9V+MJ&YT=I??0%(9<3XBLA$TE12M.5:L9MD9DRQXP0FM/._IVPWJHL^
MF+/67MAA92M]M7AISC!24I*%$I3($.9LJIX<(ZCM@ZT6$,V77#6-DVUY'"UP
MSSY*)AYI[,-;BL61FG"HMV<2:;2;,7L.]>*4(07*`("<0#S`KIGW"\J&X&B[
M(O4U"\Q<K&P1XI:3D<`)P*4%2BH<R`,`)P\[9^<W0FN[ZWIBZ4;UGNSR24J=
M<"T$B7=5)*<N;I)XB4*?9ZR_%8-P[D+,DK&2$[$X\MMW<KV,BSH(OY)LT%(`
M19+/#$:%%3S@-4Y@*(!V\=#EH^PU.L-0T6EK>2W7U=<&&\W=&<F0S$\!,\3A
M!0ZYUC2:'TC<]7U#9J*:BHC4%"<0I`Q)!&!PCA6R;>K:>]:SKQO:T+*N2S&=
MFW.E:SUC<KN->.WKIS%-Y8CI$8HZB!&R:+CE$##S5"O9K>MUMI+CM+>Z.TW>
MI1453]*7&R@&67,1B23WI@QI&RV\=EWET]57RT4CE*TS4!M060HYB)\DIF)<
M^4?+W?=07!FSIJ@QO=\_NG($JS._AL;V@#=Q<2K0A1%*1F5G"Y&$!%K']%-5
MR(&7&OEIG`!U=MGLWKK=6I<>TZTI%GID#QG71E2DXSRJ,@XKF4)Q`QYQX-W]
M_-![-48&H'D5%^>40U2M'OD2!!6)J*`>2E"1.`A*/_'TN#U\KP=KPC:!AX/C
M7\Y3?@41#T1=&ML84'(@`@4H*"034"NB";\F[B@"YJJB1<3(!DM$B:N&/B`#
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MP\2<O,0"AZ0`!BE+P#@%0`.S70UP48;0'3*L4D3'0L\!Z3`<YU+6H`]V>'H,
M_P"7R1(Y_#78NVYVAT[[?OW#<JUN;(^3+FEW>X.<=-46L_$Y"A%C-&U@.D0,
M==K"6C#*HF8$YA2<E<G<E&JH@`&;P5M\J=8.45W*DI8/[-'(IE,'TP5.VU'1
M4NGD5-.!X[^"CUC"0Y]?7T80XA#@`!]0/D^SJ+HDN,:O8'UPU:K@/UA[8QN^
MX?1$=1\4A^\RBOV:\7?C^_M&;Y>?P0Y]<<_LMP,^\GXF;_<I]L+I?"B_V"<Q
M_M/7/_0*P=1=YA?QLU]53[3$@[0?AE7UC\@A2'KH?NF-ZOZ-(;^L"SM1[MI^
M/[;]83[%1M^N_P`+5O[OYH8&]&3]ZCL=_3:P_$-QZ-?=S\`7?]PGVP,^WOXM
MM_[TQ*J%_"?[NN=37^&CL,&/^@?UHSZS19#*3J0VQ*7OU*<FV/`G$LM>-Z8Y
MMJ*.6IC$>SEMVU&I*>C01(3S^8P?R0'75G8RZLVC82CN=P*4VVBI7W9$`A:D
MJ6K$'CB)1Q,\QULJ[WYEKK96$J-96UU,T"GBE*D-IP]!$.M]OVTS"6W;'<+8
MMB6%;"1V,8V1G+A>0L8_G;GD_+*:0DYN7=M5'KX[EV)SE()P22*(%(4"@`:Y
MK:MW!U/K*_.WNY5KR@X^I3:$.%*6VB3D2$@RDD83'&.M&A=K](Z#TVU8+-04
M_C-LI#CCC8<4X[+ODJ/&9Y<!"./6@V<8V@<:1VYK'-L1-HW%#7'$6UD!G;L<
MC'Q]SQ5Q*JM8Z8=L6!$&J4Q&2Z:1#."E`ZB:M#5H`@4OE&W1N[FIJG0-]4NN
MME8RM;9<65E'A@$I,YS"@>>((PP@-?.MLW9:?2;&YVG&TT5YHGVFW&VD9,_B
M*/?PX%!`Y2(GVQN]AYKFLV]%3+SVZ7R\E=%B8[O3&LW).C&5=ORVJZC"PSIT
ML8QSKN%X!XV*90?24.03#Q'33?-',Z&\W%NLS*`W2/W5JH:2!()"^\0.Q4^R
M'VQZ\7K[R3W6Z.N_^3I;2Y3.J.).0A()[4X1H_14O1CCG:/NKR'*B`1EBWF^
MNM\3GY`4;P..$9(R(&$?1,N9L!`'Q-I_\XEI=U#N=IZTT7^/44Z&QT]Y\I']
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MHO4#P:ZZ=^[O'69\`'=6M;-Q&/D"T(MFN;U*W9:$D4$[VLD@B8!7MB6:.R""
M)N8I$'(ITH4E.D&QVJ4;^[77';S6[B'+A2HRH=5+.9I[A!Y*!ECU&.5._P!I
M>H\M^\]LU]H="6['5N>*TVDG*IW-)QM0GB)'`=!$.C?SUVU]'GZ1-0]V/S3?
MG6\OS.'J'NM[R>I\W;YG_1_G:YV_=>[_`'J^X^17Q_QOPG#O9O$\.<OEX<(Z
M<??*T_<+_428^`^S?C..$O"\3+T\>[':U"@!`&HB'``IQ$:C3LH/-Q'L\=:Z
M'%-I&3',8WCPTNN^(K@(8=_$M=3<<KY'3V#8;N!)?'6)IAM+Y\F8QSYC:[,H
MM4O-A[`%9`YRKQ./"N`7>D&G-+F*40YFH:*_8K;I3#9UP[(7!PEIM*A_RQ)6
M?'DHJ,I='$S@?-TM7-.J^[]*?V*3G4H'F9IEAT"$4\<],W/V3>GWE[J#04:Y
M''N+;SCH-O;8L%E):[+-CP7;9!R!#GY@,>"L.4=-4%0*0WG$]8/7_M]2_6[C
M66VZR9TA5+25O-+SJF))5+NCIF>79&C46C[B_IUR^MH[R%)*1+B.9[!SZ)P:
M?H4=2=QL*W3,K7R!,G;;:L_OX6S,F)N%A".LZYC.!9VAE%$@J%*W"#=.A:2A
M@#[Y&+F,(U0)K5]YMND:JT[\?0XUE$,R".*QQ(GQ,^77#MMKJ-6GKU\)6?\`
M;U9DJ?Z..!Z!QP_-$F,U=MG:"3AJNDX;+ID60<(J%51704(4Z2Z*I#&(HBJF
M8#$,`B!BB`A4-`L%.E\T]0)*'#E.7\L8*="T.ISMD%,9#4I0`$*'[^_LX_Y]
M9<Q4,>2P/EC&XHK0HG"4A$=9\4A^\RBOV:\7?C^_M&?Y>?P0Y]<<_LMP,^\G
MXF;_`'*?;"Z7PHO]@G,?[3US_P!`K!U%WF%_&S7U5/M,2#M!^&5?6/R"%(>N
MA^Z8WJ_HTAOZP+.U'NVGX_MOUA/L5&WZ[_"U;^[^:&!?1GX=4_8X;M_]VL@Y
M>%>%OW$(5`./'L#ZNC:W>4Z=NKHTDMA&0$S/>Y<O9`S[>K"=3T8\,J/BC''I
MB52K0Y1$3<`-00`1K6E:A3NUSG0YD!0O(")<Y=,&,I2LJI@A,QPQ,9/,_G_\
M`_Q:N\9'2C^L(P3ZE^KZ(:/;@5F#?K;0RDL9,C`,]X2,L=40`@%)$6V!3"8W
MH@4J_*`ZZ3:*:J%^4)U#()JDVMXR&)]]S\D<AM</,T?G7:>J#_EV[^RLD_S@
MT0#U3&$.W2\HEXB/HB(A7AQ$PCV>%-<UEA2:<R]]0E'7E99<<FK!2%3]GKA+
M?K&2L?';#,FI.UBH*2MPX_C8],X4,X?#=T<]!`@#Q$XMF*I_K%U/WE=I*FZ;
MR6H-)(0VAXK[`C'T"!=\Y52BFV*N?C*'B5%13-H',DKY=<LWJA-':/$.H_HO
M[PI%R4Q&LW(9%<QZAZ\JZ#&-M2,771$?G$!VBH2O>8@Z(O=VHHZGSCV)-*K,
MVE^@!,^!S*/L@:MGF*I'DIU94U"2`^*YU,Q*8+;2,/2DF/A=.:(DIOIE=0J,
MA?--).T;G(U*B43JJ>7C1HNJ0I`^<91!,Q?LZR^82K8HO,9I9^ID*5I;2B>`
MDI[CZ#C'B\L]$]7>677%-2`JK'F'4`#C-3"P(ZAT`YV&19;E+=%9/VVNYQO.
MH-N`K+1!&<[&G73"M3)H/3%*;P$P#WZUSSQ4;J*K3]4P"JWI6Z2J4Q-7AGV)
MA[_^?-Y8#&H[>LC[0!9<2.!(&=*I>G+@.F'(8F(4IC#7YP`/>(B(\OH^%:Z!
ME;3CA1DE,+S>CG'2IQQ%.DK/N\?2K\T-O>O].Q!DMMT#YB0S*!<F3)D!$//3
MB3(V['@J<H5$$EW20@'B*0^&CH\E"7A67ZX-)(:53MMA1&&8E1,CTRD8YL?_
M`$-K6/#TY:I@OEU;I`XA."1V8S$*%>[LQ_A&>[WJ*OMGZ&7+ZC0WG5_-_P"N
M<M.WF]7]*E*ZA7[6MO\`N2^/SC[/^\L\T\)>-*<^WG!$_955_M*^R\BOC_NC
MERXSGX$Y2XSCE_6DZE4-T[-J,K*6[+1Q=PF7R2=CX,A%EDA=,9-9J(3F0WC4
MQP4+#V,P7\\#&#D5?G;I<><0UH>V.A*O75^31-B5L;DIQ1P,L<)G"9EPE@,8
MF_6&I%6"QJ?IQFK%8`2)&.$Y"1^F(Z?:3MOR5OPW48\P'9L@\F;VRS>`N[NN
M]VHI)N(6WCN_:^0LAW&Y$R@KGC(Y1PZ454-5PY.F2HF4`-&;J"^4&A+`NI6I
M"6J5GPD(!$R4C`]IX3ER@9K'9:K5-Z2RI*PMU>99/'B293PE[(E;\4[<\3X9
MP!:.VFT+5C@Q%:./VV,4+7>MT5F<K;1HU2,EB3"9B\CQ>X/6EUGQS<5U5U##
M43:Y\5-VJKK>GKV\XL5BWLX5/@09R3,>[R[.8@OZ2VTM%;6[8T/\NVWDQYS$
ML>LQ&&]5_8=)]/3>'?\`AT[=8<4W*9>_\&S+T%"I2^-9]VX*UA1<CZ#B1LU_
MSQ3@@5/1%)0X<JH"/0#;35]/J[2*%U3K*;@PG(4\`2D2[P)F9\>(F#`FZRLK
MUDU`M!;<-,I68$<9=1EA^275#O7X;_J9%W.X,5VA9;N8DAG7;Q"M"6E(R+XB
MLGD'"Z`I,(9Z4ZAS*OI>PU13C7HAS',U,V5&M3CH7-YM#)T[?Q=Z,CX%Z:CE
MQ`6<5<.`/+KG$T[::N5=*7[.J$D5:>''%(Z>L?RX0YQY3CP$0H4U>P>SNJ->
M(ZAPA"A-/$R/I^:)3>"ED9)9#QZ9Q'4_%(J($ZF<6115,A_HV8MY0.<I:A[?
MOWF&@B`Z,KR]H4C1KP>=:0T*A1QP,R`D\^'=$H&K>!"SJ1#JD+4UX`&'3*8Y
M'GQA=#X4-0IMA.9.0Y#@&Z"YR\Q#`8*^X=A=X"(=FHO\PJFE:V;4TM*T"E3B
M,>F)"VB1/3BTA*DGQ)X],O1AA"D/70/R])G>MY@E*7\VL,`B(\H!_P"?V@-1
M$1H`<-1]MN/_`'RV+20E/Q`F3V&-HUPO+I2I+H*EJ1(A/;RXQ&/8>S-?>`LH
M61F?$]S(VMDK'4S[P6;<I&D7**0TP5NY9E>)LI5N\CW!BMW2A0*JD<OI=FC]
MOENME\HJFTW,-.TKQRDC`Y1*0G,CIY0)5#<*RT5S=;;4N)<;,QFQQZ<`.J%0
M_P#Z!^K#V_2W=5_1UBGY`M"FHZ&S^W@$OATG^E&UKW'UFMPN!U:9\@#+T"4#
M_P"@?JP_WMW7ZNL4_DAI?Z0;>?PR?ZT4_P!1M:?]9SU?1!F,"Y7W&;R;ALK*
M4[<CG(>Y&_95>8;3;)G"PDG,3]DE<.(<[!C#M(^*2D&D=!E!$A$B^<=,"T$3
M!HD=,TND-';2"WWQSX?3SE.NG<!4,R4+*A,&6!.8F9!'.4<\MTDZGU%OW4U5
MD:4[J%3K-0D!)(4ML)4``)']'$3G#I+"'6^PB-CQ,5N*MJ^+(RE#(%B[J"!M
MM:=AY&99#ZLZ=I-0<H2\(Y<*$$R[5TB46ZO,4#&"@Z"35/E7U:Y6FOT%4T%9
MIRH5GIUK?2E8"^"5)GWLHD,PE/H@XM'^=;1!MIH-PZ.OMNHZ8J0^$LJ6A2D2
M!4#(9,QG))*B)3F83QWG[P+_`.ICD2P=O6W2PKD4LYC/!)QS"33($U<MP*$%
ML6Y[F2:+NF=MVM;[!951,RRE2B<W./,)2:GS:7;"U^7BT5&X&Y%;3HU*&"E+
M;:TEL(4)J0G$E3BBD92#AB,I@?-Z-Z+IYG-0V_0.V-&^Y84U;:RM3:@2I$QG
M7R"`%&?#MA8?.6"(?;/TGLJ87C')'X6A@R:)+RG(5,LM<+YZA)W#*$`H%Y4W
M,J\5$E>()\H#V:%#26L'M>>8>UZK$P[6W5OPT$X)0T>X/5BKIZH+_7&@Z;;+
MRIWG1]$5+^$LRPM2I$J6Y+Q.`',R3U2XP5_H.L8J8V][@XAV1)_&2F4V\<_:
MJT52<LWMC,FSEJJ4`H8JZ*I@$![M2OYV'RQN':GJ0J544M`A4T'',EU2@3@<
M.$Q\L1'Y!J1NJVWOE+5H.6HK`E8/NY2VI/=!X8'I.,$$O:T<Q](/>(.0[:@7
M]RX9N)X^:0SI4BK>!O&P)MR"Z]ERLLF7U6(N^WUA`S?S"@!CHD.4HD4,!9:M
M]=IGS2[8TVGJJI%+K2E!.0"0#B4@!1F9EM741T9IQ!-?I_6OE`WC.H[?3.5V
MAGLP\7*I84RZK%"LLAXK<ACTXY9&%7%NN/M'+:A9A.%RJ:Y@;E/[F#:;4')'
M5**-U+A]J&@033,(56\SEY*B`5X:'1/E$WE^U_@7&Z,,%T2<#HD$`XDCI(QX
MP5J_/%LPBRJK&?CEUJ`E/@J9()69R`<X2$C^CC"3]FVAFKJ_;N4\A7/".K;P
MY;SR/;7&Z2]9-`69CV(7.JE9<#(G*"$U>5T*B?UDZ!A*05CJ*`!"I@)(WZOT
MIY6-K3IZWU3-;K.J.=:003XA$ID)Q2A/('HXS@5;+IO7'FYWD.J+S3.T6C6@
M$H5E4$I9000$E6!4KF>9Y0[D]V8?W<]TO9S;W;]A^[?LGE#U;V%ZA[+]F\G9
MY'L_[U3^3KFU\2]\3\=/_-9\^;GFGFGVSCK;\%2_`?9>1/P7@^%EY9,N7+V2
MPCEN2]M6`<T2<7,Y@P?BC*DM"LEXR(D\AV);-XOXJ-<N"N5F$:ZN",D%F+19
MP0%%$TS%*8X`(Z]5ON]XM,S;*MQDJXY9CV$194VJVUJ<M6@+'01'CQUM:VXX
MAN!>Z,3X`P[C&XEXQ6)5N&P<=6A:<VO&N%"*N8U24@HAB^%BX413$Z?F<AQ*
M%>S5UQO-XNC/A7"J<>3FG)1)]IC%36>VT=1\72LH14!.4$?\,=\*4P<!I0*4
M\:?Z--13.1`D1AZX=%D'W>,<=RGMZP=FY6&7S!AO%V5%[<([)`*Y%L:V[Q/#
MD?BD+Y.,-/1STS`KP42"IY0EYQ(6O9ISH;M<K8E0MS[C14<<IE.&^KMU#7O)
M56LH<0GF>/YHUZP=INV+%5SMKUQCMTPGCJ\&+9VT9739.-+.M>X&S5^D"+]J
MC+PD0R?IMGB/HJI@IR*`%#`.JUE\O5U0:>Z/N.T_(*5/VQCI[/;*%9?H64(?
M/,808(H*5&I``.8>(&J/@`CP\`TVHF$E)PE@.SE#CX;<IS.8XGMC@^1MK6V[
M+]PEN[*^`,-9*NE..;Q"=Q7YCFT;MFPBVBJRK2/+*ST0^>D9-CN%#$3`X$*)
MQH''3@S>KW;J4T]LJ'$))GE"B$GM$-]3:Z"O5FKF4+(Z<8W'&^'L78:A'=N8
M@QK8>+X!](GEWD%8-KPMHQ#N5521;K2;EA`LV359\HW;ID,J8@G,5,H"-`"F
M"JKJ^XU8J;@ZIU8;E-1F>SLCV4=)1T+?@TJ`VWT`81L5ZV1:.1K8E[+OVUK>
MO6T;@0(UG;6NJ)8SEOR[4BR;@K>2B9)NZ8OD2KHD.!%4S%YB@/=JQI]^F>34
M4JRAY!F","(J\RS4(\%](4R>(,%O^@3LE```=GNV4>`!PPGCB@``4``#W=``
MH`=P`&GLZKU-^C7/@=:B?EF(:5Z?LF;NT;2ATR`_)`^@3LD_N>;9OU)XX_)[
M5/O5JC^/>]:OGBS[OV7^"9^3YH'T"=DG]SS;-^I/''Y/:7WJU1_'O>M7SPON
M_9?X)GY/FC?+2VM[<\?/8B2L'`N'K*D(%<7,*^M;'5IP;R)<'`_,XC',?%-U
M&2_WP?33Y34$>.J5FI]1W*C717*NJ7J=8Q25JRG^B21#?3:(TE17=-^IK93)
MO".#LAFQZY1J&3]D6U/,TVXN?)N![`NJY72H'=SR\6,=+/C%+R`K(/X9:-<O
MU.7A58QS4`.(Z?=/;J[E:0HQ;=.7>L8MPQ\)*QD!/$@+2J1.$Y2X1KVH]E=J
M-6W%=VU'8J"LN*Y9G%H(49<!-)3@/SQT3%.WS#>#F2D?B/%]CX];N$R(NAMF
M#9L'CQ$AJ@#^3`BDE("4>(><J?CI@OVJ]4ZKJ#5:EK7ZM9'!:B1/D9"2?4(V
M#36@]&:09\#2]KI;>D)(!:2)]D^,CVQTBX;;A[KAI"W;FA(JX(&7:'92D-,M
M&TE%2+57\(V?Q[M-1L[:J<H<Q#@(#X:9:9ZIM[S51;EEFJ9,T.))"D'I3+'U
M$1L%;04MVM[EONS27J-T%+C2L4K3U_-*-=L3%M@8R9/HW'MC6A8K"3=%?23&
MSX&-MYF_>%1*@5TZ;QC=NDLZ(B0"`<P"($"FG"Y7F\7FH357>J>J'TB0+BBL
MR[29PW6;2VG=/4BJ*P4C5%3.F:TMB0)C[%UV9;-[PCZW+OMN"NJ`D4A1?P5P
MQK66BWR5!`"N&3U)5LIP$>)BB(:\=%6W*VU8KK:\:>L$I+1F"I#$8A0CTW2Q
M6>_47V9>J9JHMLS-#B0H'KQYP4HO3?V0%D2RP;9\9`[\TJXI@P?'8%4+40`L
M4H_&*Y#"/$OD@40[M2(G>7=A-*:(WZL533&!(EAPZYCMB+!Y=-D&JTW"GTY0
M(J\T\R4J!QXX9BG'H`@W%KV=;5D0;*VK/M^&M>WXY,$F$)`1S2)BF28```1L
MR9))()!0O&@5'4>U]9776O-RNC[K]4>*EJ*B2>LQ+-%:K;:J--MM3#=/0I&"
M4`"7JC:=>>'"+"F$1H-.S2A1?I0HH8:`(Z4**%&H5'QTH47:4*!I0H&E"@:4
G*!I0H&E"@:4*!I0H&E"@:4*!I0H&E"@:4*!I0H&E"@:4*!I0H__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
